ALFA Finder| Revenue growth | 25% YoY growth guided for FY27. |
|---|---|
| Margins | EBITDA margins targeted at 20-22% for FY27. |
| Order book | Stable order flows; good visibility for next 12 months. |
| Demand visibility | Strong visibility in PASC and SDA; Euro 7 norms drive SDA. |
| Management confidence | High; visibility until end of CY26 for orders. |
Growth
FY26 revenue exceeded ₹500 crores. Electrolyte Salts segment saw exceptional 1,378% YoY growth in Q4.
Outlook
FY27 guidance maintained at 25% revenue growth with 20-22% EBITDA margins. Capex of ₹100cr planned for FY27.
Risks
Geopolitical conflicts leading to rising fuel and raw material (crude/ammonia) costs; semiconductor commercialization gestation period.
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,655.00
- Market cap
- ₹3,871 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 61.5×Sector 35.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Q2 FY27 Results: Net Profit ₹21.5 Cr, Up 117.2% YoY
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹21.5 Cr · +117.2% YoY
Tatva Chintan Pharma Chem Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.